People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin. The investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke. The purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Warfarin
Locally approved DOACs
Feasibility - Recruitment
Recruitment rate; 1 patient per month per center at 9 Canadian stroke centers
Time frame: From site activation until the end of recruitment (approximately 24 months)
Feasibility - Adherence to Assigned Medication
Proportion of participants who cross-over (i.e., vitamin K antagonist to DOAC, or DOAC to vitamin K antagonist) is \<5%
Time frame: Enrollment to final visit (average 12 months)
Feasibility - Retention
Retention of ≥95% of study participants
Time frame: At 6 months from randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.